X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ribavirin (5) 5
health aspects (4) 4
hepatitis c virus (4) 4
index medicus (4) 4
liver cirrhosis (4) 4
proteases (4) 4
aged (3) 3
antiviral agents - therapeutic use (3) 3
direct-acting antivirals (3) 3
drug therapy, combination (3) 3
female (3) 3
gastroenterology & hepatology (3) 3
hcv (3) 3
hepacivirus - genetics (3) 3
hepatitis c (3) 3
hepatitis c, chronic - drug therapy (3) 3
humans (3) 3
male (3) 3
medical research (3) 3
medicine, experimental (3) 3
middle aged (3) 3
ritonavir (3) 3
virus diseases (3) 3
abridged index medicus (2) 2
abt-450/r-ombitasvir (2) 2
adult (2) 2
anilides - administration & dosage (2) 2
anilides - therapeutic use (2) 2
antiviral agents (2) 2
antiviral agents - adverse effects (2) 2
biological response modifiers (2) 2
carbamates - administration & dosage (2) 2
carbamates - therapeutic use (2) 2
care and treatment (2) 2
chronic infection (2) 2
cirrhosis (2) 2
compensated cirrhosis (2) 2
dasabuvir (2) 2
gastroenterology (2) 2
genetic aspects (2) 2
genotype (2) 2
genotypes (2) 2
hepatitis (2) 2
hepatitis c, chronic - complications (2) 2
hepatitis c, chronic - virology (2) 2
infections (2) 2
liver (2) 2
liver cirrhosis - drug therapy (2) 2
liver cirrhosis - virology (2) 2
macrocyclic compounds - administration & dosage (2) 2
macrocyclic compounds - therapeutic use (2) 2
pibrentasvir (2) 2
protease inhibitors (2) 2
ritonavir - administration & dosage (2) 2
ritonavir - therapeutic use (2) 2
sofosbuvir (2) 2
treatment outcome (2) 2
velpatasvir (2) 2
virology (2) 2
abdominal surgery (1) 1
abnormalities (1) 1
administration, oral (1) 1
adolescent (1) 1
age distribution (1) 1
aged, 80 and over (1) 1
alanine (1) 1
alanine transaminase (1) 1
alanine transaminase - drug effects (1) 1
analysis (1) 1
anilides - adverse effects (1) 1
antiviral agents - administration & dosage (1) 1
antiviral agents - blood (1) 1
antiviral drugs (1) 1
asia (1) 1
aspartate aminotransferases - drug effects (1) 1
benzimidazoles - adverse effects (1) 1
benzimidazoles - blood (1) 1
benzimidazoles - therapeutic use (1) 1
burden (1) 1
carbamates - adverse effects (1) 1
carrier proteins - antagonists & inhibitors (1) 1
chronic hcv (1) 1
chronic hepatitis c (1) 1
clinical-trials (1) 1
colorectal surgery (1) 1
combination (1) 1
daas (1) 1
daclatasvir (1) 1
direct‐acting antivirals (1) 1
drug administration schedule (1) 1
drug combinations (1) 1
drug resistance, viral (1) 1
drug therapy (1) 1
enzyme inhibitors - administration & dosage (1) 1
enzyme inhibitors - adverse effects (1) 1
enzyme inhibitors - therapeutic use (1) 1
epidemiology (1) 1
europe (1) 1
g/p (1) 1
gangliosides (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 557 - 565
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Glecaprevir/pibrentasvir | Hepatitis C virus | Surgical Oncology | Direct-acting antivirals | ASIA | PHASE-3 TRIAL | RIBAVIRIN | COMPENSATED CIRRHOSIS | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Anilides - therapeutic use | Age Distribution | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Sulfonamides - blood | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - blood | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Drug Administration Schedule | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Viral Nonstructural Proteins - genetics | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Virus diseases | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | Genetic aspects | Health aspects | Liver cirrhosis | Cirrhosis | Antiviral agents | Ritonavir | Chronic infection | Proteinase inhibitors | Hepatitis C | Patients | Genotypes | Glecaprevir | pibrentasvir | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal of Hepatology, ISSN 0168-8278, 05/2019, Volume 70, Issue 5, pp. 1019 - 1023
Curative treatment of patients who previously failed hepatitis C virus (HCV) therapies is critical to achieving HCV elimination. Glecaprevir/pibrentasvir (G/P)... 
Resistance | Retreatment | G/P | HCV | RAS | SOFOSBUVIR | OPEN-LABEL | RIBAVIRIN | HCV INFECTION | GENOTYPE 1 | VELPATASVIR | PIBRENTASVIR | CLINICAL-TRIALS | RESISTANCE-ASSOCIATED SUBSTITUTIONS | GASTROENTEROLOGY & HEPATOLOGY | ANTIVIRAL DRUGS | Hepatitis C
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 4, pp. 971 - 980.e1
Background & Aims Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with... 
Gastroenterology and Hepatology | Direct-Acting Antivirals | Interferon-Free/Ribavirin-Free | HCV Genotype 1b | ABT-450/R-OMBITASVIR | CHRONIC HCV | RANDOMIZED-TRIAL | RIBAVIRIN | PEGINTERFERON ALPHA-2A | PLUS SOFOSBUVIR | DASABUVIR | TREATMENT-EXPERIENCED PATIENTS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Recurrence | Anilides - therapeutic use | United States | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Enzyme Inhibitors - administration & dosage | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Female | Drug Therapy, Combination | Enzyme Inhibitors - adverse effects | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Administration, Oral | Antiviral Agents - therapeutic use | Europe | Carrier Proteins - antagonists & inhibitors | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Enzyme Inhibitors - therapeutic use | Remission Induction | Macrocyclic Compounds - therapeutic use | Hepacivirus - enzymology | Liver Cirrhosis - virology | Anilides - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Medical research | Proteases | Ritonavir | Analysis | Liver | Medicine, Experimental | Biological response modifiers | Hepatitis C virus | Health aspects | Gangliosides | Liver cirrhosis
Journal Article
Health Science Reports, ISSN 2398-8835, 03/2019, Volume 2, Issue 3, pp. e92 - n/a
Background and Aims AGATE‐I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and... 
DAAs | compensated cirrhosis | HCV | genotype 4
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.